Background and Objectives : Beyond lowering lipids, statins are known to possess antiinflammatory and antithrombotic properties. Recent studies suggested an association between statins and early reduction in death or myocardial infarction after percutaneous coronary intervention (PCI). The aim of this study was to examine the interrelationship between inflammation, statin use and PCI outcomes in patients with acute myocardial infarction (AMI). Subjects and Methods : A total of 340 patients with AMI who underwent PCI between June 2000 and Dec 2001 at Chonnam National University Hospital were divided into two groups: Group I (n=158, 58.9짹10.7 years, male 82.9%) with normal C-reactive protein (CRP) (<0.5 mg/dL, mean value=0.41짹0.14 mg/dL) on admission and Group II (n=182, 60.1짹12.4 years, male 83.5%) with elevated CRP (���0.5 mg/dL, mean value=3.71짹1.73 mg/dL) on admission. Results : The levels of erythrocyte sedimentation rate, white blood cell, monocyte, creatine kinase (CK), CK-MB, troponin I and T were higher in Group II than in Group I. Severe coronary lesions (type B2/C lesion) according to American College of Cardiology/American Heart Association were more frequently observed in Group II than in Group I. During one year clinical follow up, there was no significant differences in major adverse cardiac events (MACE) in Group I, but in Group II, death (8.1 vs. 1.7%, p=0.033), restenosis (35.5 vs. 20.8%, p=0.032) and target lesion revascularization rate (33.9 vs. 20.0%, p=0.040) at 6-month follow-up angiogram were occurred more frequently in patients without statin therapy. In Group I, the event-free survival (EFS) was 74.1% without statin therapy, 81.0% with statin therapy (p=0.312), and in Group II, the EFS was 51.6% without statin therapy, 78.3% with statin therapy (p<0.001). Using multiple logistic regression analysis, independent predictors for one year MACE were CRP above 0.5 mg/dL, left ventricular ejection fraction less than 40%, old age above 75 years, statin use, and type B2/C lesion on coronary angiogram (p<0.001, =0.001, 0.002, 0.031, 0.035, respectively). Conclusions : Statin therapy significantly attenuates the increased risk for MACE in AMI patients with elevated CRP levels undergoing PCI.